These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 30267753

  • 1. Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms.
    Ye T, Sun S, Sugianto TD, Tang P, Parumasivam T, Chang YK, Astudillo A, Wang S, Chan HK.
    Int J Pharm; 2018 Dec 01; 552(1-2):130-138. PubMed ID: 30267753
    [Abstract] [Full Text] [Related]

  • 2. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HDC.
    J Pharm Sci; 2018 Aug 01; 107(8):2172-2178. PubMed ID: 29698726
    [Abstract] [Full Text] [Related]

  • 3. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HDC.
    Mol Pharm; 2018 Apr 02; 15(4):1643-1652. PubMed ID: 29514003
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2008 Apr 02; 31(4):329-36. PubMed ID: 18280117
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2009 Oct 02; 34(4):370-4. PubMed ID: 19505804
    [Abstract] [Full Text] [Related]

  • 6. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
    Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A.
    Int J Pharm; 2009 May 21; 373(1-2):141-6. PubMed ID: 19429299
    [Abstract] [Full Text] [Related]

  • 7. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
    Thellin O, Zorzi W, Jolois O, Elmoualij B, Duysens G, Cahay B, Streel B, Charif M, Bastin R, Heinen E, Quatresooz P.
    Int J Antimicrob Agents; 2015 Jul 21; 46(1):33-8. PubMed ID: 25963337
    [Abstract] [Full Text] [Related]

  • 8. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa.
    Alipour M, Dorval C, Suntres ZE, Omri A.
    J Pharm Pharmacol; 2011 Aug 21; 63(8):999-1007. PubMed ID: 21718282
    [Abstract] [Full Text] [Related]

  • 9. Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa Biofilms.
    Du J, Bandara HM, Du P, Huang H, Hoang K, Nguyen D, Mogarala SV, Smyth HD.
    Mol Pharm; 2015 May 04; 12(5):1544-53. PubMed ID: 25793309
    [Abstract] [Full Text] [Related]

  • 10. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT, Sun SP, Chan JG, Wang P, Barraud N, Rice SA, Wang J, Li J, Chan HK.
    Mol Pharm; 2015 Aug 03; 12(8):2594-603. PubMed ID: 25423590
    [Abstract] [Full Text] [Related]

  • 11. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
    Pilcer G, De Bueger V, Traina K, Traore H, Sebti T, Vanderbist F, Amighi K.
    Int J Pharm; 2013 Jul 15; 451(1-2):112-20. PubMed ID: 23643509
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
    Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP.
    Antimicrob Agents Chemother; 2010 Oct 15; 54(10):4409-15. PubMed ID: 20696878
    [Abstract] [Full Text] [Related]

  • 13. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
    Pilcer G, Rosière R, Traina K, Sebti T, Vanderbist F, Amighi K.
    J Pharm Sci; 2013 Jun 15; 102(6):1836-1846. PubMed ID: 23568616
    [Abstract] [Full Text] [Related]

  • 14. Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
    Porsio B, Cusimano MG, Schillaci D, Craparo EF, Giammona G, Cavallaro G.
    Biomacromolecules; 2017 Dec 11; 18(12):3924-3935. PubMed ID: 29111673
    [Abstract] [Full Text] [Related]

  • 15. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J, Kutter JP, Mu H, Moodley A, Yang M.
    Int J Pharm; 2020 Nov 30; 590():119877. PubMed ID: 32927003
    [Abstract] [Full Text] [Related]

  • 16. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
    Halwani M, Blomme S, Suntres ZE, Alipour M, Azghani AO, Kumar A, Omri A.
    Int J Pharm; 2008 Jun 24; 358(1-2):278-84. PubMed ID: 18448284
    [Abstract] [Full Text] [Related]

  • 17. Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
    Rojo-Molinero E, Macià MD, Rubio R, Moyà B, Cabot G, López-Causapé C, Pérez JL, Cantón R, Oliver A.
    Antimicrob Agents Chemother; 2016 May 24; 60(5):2912-22. PubMed ID: 26926631
    [Abstract] [Full Text] [Related]

  • 18. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J, Klinger-Strobel M, Arnold K, Thamm J, Hartung A, Pletz MW, Makarewicz O, Fischer D.
    Eur J Pharm Biopharm; 2018 Oct 24; 131():120-129. PubMed ID: 30063969
    [Abstract] [Full Text] [Related]

  • 19. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
    Lababidi N, Ofosu Kissi E, Elgaher WAM, Sigal V, Haupenthal J, Schwarz BC, Hirsch AKH, Rades T, Schneider M.
    J Control Release; 2019 Nov 28; 314():62-71. PubMed ID: 31654686
    [Abstract] [Full Text] [Related]

  • 20. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Craparo EF, Porsio B, Schillaci D, Cusimano MG, Spigolon D, Giammona G, Cavallaro G.
    Nanomedicine (Lond); 2017 Jan 28; 12(1):25-42. PubMed ID: 27879162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.